Jan 26, 2022 9:00am EST iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease
Dec 22, 2021 9:25am EST iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022
Dec 21, 2021 9:20am EST iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting
Nov 30, 2021 8:00am EST ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting
Nov 29, 2021 8:45am EST Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202
Nov 17, 2021 4:30pm EST Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting
Nov 15, 2021 4:05pm EST iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update
Nov 15, 2021 1:00pm EST iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors
